Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Oxygen Deprivation Activates Tumor Survival Genes in Solid Tumors

By LabMedica International staff writers
Posted on 15 Mar 2015
A possible new approach for treating reoccurring tumors would target the protein hypoxia-inducible gene domain family member 1A (Higd1a).

Higd1a is a survival factor induced by hypoxia-inducible factor 1 (HIF-1). More...
HIF-1 regulates many responses to oxygen deprivation but is frequently absent in viable cells within the hypoxic perinecrotic regions of solid tumors. Cells in this region are deprived of both oxygen and nutrients, which promote their resistance to therapy.

Since Higd1a decreases tumor growth but promotes tumor cell survival in vivo, investigators at the University of California, San Francisco (USA) have examined how the HIGD1A gene becomes activated in the absence of its usual inducer, HIF-1.

They reported in the February 12, 2015, online edition of the journal Cell Reports that the human HIGD1A gene was located on chromosome 3p22.1, where many tumor suppressor genes reside. Consistent with this, the HIGD1A gene promoter was differentially methylated in human cancers, preventing its hypoxic induction. However, when hypoxic tumor cells were confronted with glucose deprivation, DNA methyltransferase activity was inhibited, enabling HIGD1A expression, metabolic adaptation, and possible dormancy induction. Under these conditions Higd1a protein was available to interact with the mitochondrial electron transport chain to repress oxygen consumption, enhance AMPK (AMP-dependent kinase) activity, and lower cellular ROS (reactive oxygen species) levels.

Studies conducted in vivo with tumor cells that had been genetically engineered to overexpress HIGD1A, demonstrated dramatically repressed tumor growth but significantly enhanced overall tumor survival, and these effects were even seen in mice that lacked the HIF-1 protein.

Based on these results, the authors suggested that, "Our findings therefore reveal important new roles for this family of mitochondrial proteins in cancer biology."

Related Links:

University of California, San Francisco



Gold Member
Respiratory Syncytial Virus Test
OSOM® RSV Test
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Gold Member
Immunochromatographic Assay
CRYPTO Cassette
Gold Member
Collection and Transport System
PurSafe Plus®
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Industry

view channel
Image: The LIAISON NES molecular point-of-care platform (Photo courtesy of Diasorin)

Diasorin and Fisher Scientific Enter into US Distribution Agreement for Molecular POC Platform

Diasorin (Saluggia, Italy) has entered into an exclusive distribution agreement with Fisher Scientific, part of Thermo Fisher Scientific (Waltham, MA, USA), for the LIAISON NES molecular point-of-care... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.